Legend Biotech Corp.
Legend Biotech Corp. welcomes the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy. Today, Legend Biotech's research is focused on continuous innovation in the field of cell therapy. Legend Biotech is also future focused on emerging technologies that can help address some of the most chronic and life-threatening diseases.
Location of Key Operations
Ernst & Young LLP
IPO (June 5, 2020)
Somerset, NJ, USA
Jessie Yeung, Internal
June 1, 2021: Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings - Legend Biotech
April 30, 2021: Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma - Legend Biotech